Connect with others who understand.

Sign up Log in
Resources
About MyMSTeam
Powered By
See answer
MULTIPLE SCLEROSIS
NEWS

Large-Scale Study Finds Disease-Modifying Drugs Lead to Fewer MS Hospitalizations

Medically reviewed by Evelyn O. Berman, M.D.
Posted on February 11, 2022

  • A recent study found that disease-modifying drugs (DMDs) reduced hospitalization rates for people with multiple sclerosis (MS) and help long-term in saving on health care costs.
  • DMDs delivered orally or through transfusions were associated with a 29 percent decrease in hospital stays.

The use of disease-modifying drugs for multiple sclerosis can lead to fewer hospital stays and long-term savings on medical expenses, a recent study found. Hospitalization rates were as much as 44 percent lower, depending on the type of DMD a person was taking.

“Our findings provide real-world evidence that will help people living with MS and their doctors make decisions about treatments,” Dr. Huah Shin Ng, a postdoctoral fellow at the University of British Columbia and lead author of the study, told MyMSTeam. “Fewer hospital stays could represent a major health care cost avoidance and lower disease burden for people with MS and their families.”

DMDs are a class of treatments that work to reduce inflammation in people with MS. They can help stave off relapses in people with relapsing forms of the disease, and they may reduce the severity of relapses as well.

For the study, published in Multiple Sclerosis Journal, the research team reviewed data collected over a 22-year period to evaluate the outcomes of more than 35,000 people with MS across four Canadian provinces. In addition, they looked at prescription records to track the use of DMDs for MS, including the type of drug.

Dr. Ng stressed the value of looking at such a large pool of data. “Few regions across the world have access to such comprehensive and population-based health data which can be used to study the benefits and risks of MS drugs in everyday, real-world clinical practice,” Dr. Ng noted.

Although using DMDs did not affect the number of doctor visits that people with MS made, it did reduce hospitalizations. In fact, people with MS on DMDs experienced a 24 percent lower hospitalization rate than people with MS who were not on DMDs, the study found.

Oral or infusion-based DMDs were associated with a 29 percent decrease in hospital stays. However, this number depended on the type of drug. For example, teriflunomide (sold as Aubagio) alone decreased hospitalizations by 18 percent. Another drug, fingolimod (sold as Gilenya), decreased hospitalizations by 44 percent.

The team hypothesized that DMDs may have reduced hospital stays because of their effectiveness in reducing the severity and number of relapses.

Posted on February 11, 2022

A MyMSTeam Member

Getting a single-payer medical system only remedies cost. If this were accomplished we'd still have a garbage healthcare system. Control must be taken away from pharma to make health the main concern… read more

March 9, 2022
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
Evelyn O. Berman, M.D. is a neurology and pediatric specialist and treats disorders of the brain in children. Review provided by VeriMed Healthcare Network. Learn more about her here.
Jocelyn Solis-Moreira is a journalist covering health and science. She received a graduate degree in psychology concentrating on behavioral neuroscience. Learn more about her here.

Related Articles

This fall and winter, the Centers for Disease Control and Prevention (CDC) expects the number of...

3 Layers of COVID-19 Protection: New Vaccines, Prevention Drug, and Tests

This fall and winter, the Centers for Disease Control and Prevention (CDC) expects the number of...

Recent Articles

Researchers have found that multiple sclerosis (MS) and thyroid disease frequently occur together.

MS and Thyroid Disease: Can You Have Both?

Researchers have found that multiple sclerosis (MS) and thyroid disease frequently occur together.
Do you ever walk into a room and forget why you went in there? Or struggle to find the right word...

Dementia and Multiple Sclerosis: Can MS Cause Dementia?

Do you ever walk into a room and forget why you went in there? Or struggle to find the right word...
Living with multiple sclerosis (MS) is already tough, but ataxia — the inability to control muscl...

Ataxia in Multiple Sclerosis: 7 Symptoms of Poor Muscle Control

Living with multiple sclerosis (MS) is already tough, but ataxia — the inability to control muscl...
People with multiple sclerosis (MS) have a higher risk of stroke compared to those without the co...

Multiple Sclerosis and Stroke: Does MS Raise the Risk?

People with multiple sclerosis (MS) have a higher risk of stroke compared to those without the co...
If you’re living with multiple sclerosis (MS), it’s important to understand how this condition af...

6 Ways Multiple Sclerosis Affects the Heart

If you’re living with multiple sclerosis (MS), it’s important to understand how this condition af...
You look in the mirror, and something’s different. One side of your face is drooping. The muscles...

Bell’s Palsy and MS: Can MS Cause Face Droop?

You look in the mirror, and something’s different. One side of your face is drooping. The muscles...
MS News

Thank you for subscribing!

Become a member to get even more: